HOME > 業績

Publications

(*Corresponding author)（○：当研究室が主となって行った研究成果)

2011

  1. Furu M, Kajita Y, Nagayama S, Ishibe T, Shima Y, Uejima D, Aoyama T, Nakayama T, Nakamura T, Nakashima Y, Ikegawa M, Imoto S, Katagiri T, Nakamura Y, Toguchida J. Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene. 2011, in press [PubMed]
  2. Park J, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6) disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011;13:320-6. [PubMed]

2010

  1. Ajiro M, Nishidate T, Katagiri T, Nakamura Y. Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis. Int J Oncol. 2010;37:1085-93. [PubMed]
  2. Kim JW, Fukukawa C, Nishidate T, Katagiri T, Nakamura Y. Involvement of C12orf32 overexpression in breast carcinogenesis. Int J Oncol. 2010;37:861-7. [PubMed]
  3. Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res. 2010;70:5829-39. [PubMed]
  4. Fukukawa C, Ueda K, Nishidate T, Katagiri T, Nakamura Y. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer 2010;49:861-72. [PubMed]
  5. Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of MUC1 glycosylation by transactivated GALNT6 (UDP-N-acetyl-D- galactosamine: polypeptide N-acetylgalactosaminyl transferase-6) in mammary carcinogenesis. Cancer Res. 2010;70:2759-69. [PubMed]
  6. Park JH, Nishidate T, Nakamura Y, Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2010;101:403-11. [PubMed]

2009

  1. Ueki T, Park JH, Nishidate T, Kijima K, Hirata H, Nakamura Y, Katagiri T. Ubiquitination and downregulation of BRCA1 by UBE2T overexpression in human breast cancer cells. Cancer Res. 2009;69:8752-60. [PubMed]
  2. Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, Park JH, Nishidate T, Daigo Y, Nakamura Y. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 2009; 35:673-81. [PubMed]
  3. Kim JW, Akiyama M, Park JH, Lin ML, Shimo A, Ueki T, Daigo Y, Tatsuhiko T, Nishidate T, Nakamura Y, Katagiri T. Activation of an estrogen/ estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 2009;100:1468-78. [PubMed]
  4. Lin ML, Fukukawa C, Park JH, Naito K, Kijima K, Shimo A, Ajiro M, Nishidate T, Nakamura Y, Katagiri T. Involvement of overexpression of G-patch domain containing 2 in breast carcinogenesis. Cancer Sci. 2009;100:1443-50. [PubMed]
  5. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227-33.
  6. Hanaoka H, Katagiri T, Fukukawa C, Yoshioka H, Yamamoto S, Iida Y, Higuchi T, Oriuchi N, Paudyal B, Paudyal P, Nakamura Y, Endo K. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10. Annuals of Nuclear Medicine, 2009;23:479-85.
  7. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato T, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Shiwa M, Nakamura Y, Daigo Y. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 2009; 9:2182-92.
  8. Dobashi S, Katagiri T, Hirota E, Ashida S, Daigo Y, Shuin T, Fujioka T, Miki T, Nakamura Y. Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells. Oncol Rep. 2009;21:305-12. [PubMed]
  9. Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y, Katagiri T. Activation of non-canonical Dvl-Rac1-JNK pathway by Frizzled-homologue 10 (FZD10) in human synovial sarcoma. Oncogene. 2009; 28:1110-20. [PubMed]
  10. Nagayama S, Yamada E, Kohno Y Aoyama T., Fukukawa C, Kubo H, Watanabe G, Katagiri T, Nakamura, Y, Sakai Y, Toguchida J. Inverse correlation of the upregulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci. 2009;99: 2315-26.

2008

  1. Inoue H, Iga M, Nabeta H, Yokoo T, Suehiro Y, Okano S, Inoue M, Kinoh H, Katagiri T, Takayama K, Yonemitsu Y, Hasegawa M, Nakamura Y, Nakanishi Y, Tani K. Non-transmissible SeV encoding GM-CSF is a novel and potent vector system to produce autologous tumor vaccines. Cancer Sci. 2008;99:2315-26.
  2. Konda R, Sugimura J, Sohma F, Katagiri T, Nakamura Y, Fujioka T. Over Expression of Hypoxia-Inducible Protein 2, Hypoxia-Inducible Factor-1 alpha and Nuclear Factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol. 2008;180:481-5.
  3. Ueki T, Nihidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless /RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene. 2008;27:5672-83
  4. Fukukawa C, Hanaoka H, Nagayama S, Toguchida J, Endo K, Nakamura Y, Katagiri T. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008; 99:432-40
  5. Kamatani Y, Matsuda K, Ohishi T, Ohtsubo S, Yamazaki K, Iida A, Hosono N, Kubo M, Yumura W, Nitta K, Katagiri T, Kawaguchi Y, Kamatani N, Nakamura Y. Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population. J Hum Genet. 2008;53:64-73.
  6. Shimo A, Tanikawa C, Lin ML, Nishidate T, Matsuda K, Ueki T, Park JH, Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T. Involvement of KIF2C/MCAK overexpression in mammary carcinogenesis. Cancer Sci. 2008;99:62-70.
  7. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Furukawa Y, Nakamura Y, Matsuda K. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene. 2008;27:1562-71.